Email this article What are the harms and benefits of using pegylated liposomal doxorubicin in women with recurrent epithelial ovarian cancer, alone or in combination with other drugs? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
- Issue: Vol 26, No 3 (2024)
- Pages: 395-396
- Section: Articles
- URL: https://journal-vniispk.ru/1815-1434/article/view/275848
- DOI: https://doi.org/10.26442/18151434.2024.3.202892
- ID: 275848
Cite item
Full Text
Abstract
This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2023, Issue 7. Art. No.: CD006910. DOI: 10.1002/14651858.CD006910.pub3.
Full Text
##article.viewOnOriginalSite##Supplementary files
